PFE - Pfizer Inc.
40.58 -0.13 (-0.32%)
After hours: 7:14PM EDT
| Previous Close | 40.81 |
| Open | 40.84 |
| Bid | 0.00 x 4000 |
| Ask | 40.91 x 29200 |
| Day's Range | 40.54 - 41.03 |
| 52 Week Range | 32.32 - 41.64 |
| Volume | 16,448,577 |
| Avg. Volume | 20,170,084 |
| Market Cap | 238.136B |
| Beta | 0.96 |
| PE Ratio (TTM) | 10.87 |
| EPS (TTM) | 3.74 |
| Earnings Date | Oct 29, 2018 - Nov 2, 2018 |
| Forward Dividend & Yield | 1.36 (3.33%) |
| Ex-Dividend Date | 2018-08-02 |
| 1y Target Est | 40.60 |
Market Realist•11 hours agoPfizer Expected to Report Robust EPS Rise in Fiscal 2018
In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 adjusted diluted earnings per share (or EPS) guidance from the previously projected range of $2.90–$3.00 to $2.95–$3.05. The midpoint of this updated EPS range implies a year-over-year (or YoY) rise of around 13%. While the company has completed share repurchases worth $6.1 billion to date in 2018, Pfizer has not factored in the impact of any additional share repurchases in its adjusted diluted EPS prediction for fiscal 2018. The company expects dilution due to share-based employee compensation to partly offset the impact of share repurchases in fiscal 2018.
Market Realist•12 hours agoHow IBM’s Global Business Services Unit Is Doing
IBM’s (IBM) Global Business Services unit, which represents ~21% of its total business, comprises its consulting, global business services, and application management offerings. In the last five quarters, the segment has grown 0.6% compounded annually, driven by improvement in its consulting business.
- Market Realist•yesterday
How GlaxoSmithKline’s Segments Have Performed
As discussed, GlaxoSmithKline’s three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare—all saw YoY (year-over-year) revenue growth in the second quarter, as shown in the graph below. Pharmaceuticals revenue fell 3% YoY to ~4.2 billion British pounds, as a result of 1% operating revenue growth and a 4% impact by foreign exchange. ...
- Market Realist•yesterday
How GlaxoSmithKline’s Valuation Compares with Peers’
Global pharmaceutical company GlaxoSmithKline (GSK) is aiming for sustainable growth by focusing on its business beyond pharmaceuticals. The company, which reports its financial results in British pounds, beat analysts’ EPS and revenue estimates of ~26.1 pence and 7.2 billion pounds in Q2 2018, reporting EPS of 28.1 pence and revenue of 7.3 billion pounds. The chart below shows GlaxoSmithKline’s revenue and EPS since the first quarter of 2017.
Motley Fool•2 days ago3 Beaten-Down Biotech Stocks: Can They Recover?
Is there a light at the end of the tunnel?
Markit•4 days agoSee what the IHS Markit Score report has to say about Pfizer Inc.
Pfizer Inc NYSE:PFE
Motley Fool•4 days agoGlycoMimetics (GLYC) Q2 2018 Earnings Conference Call Transcript
GLYC earnings call for the period ending June 30, 2018.
- InvestorPlace•4 days ago
GlycoMimetics Stock Has Substantial Upside
GlycoMimetics (NASDAQ:GLYC) issued a second quarter earnings report that investors will like. Its cash position was at high enough levels to cover future operational needs. GlycoMimetics ended the second quarter (Jun. 30, 2018) with $229.4 million in cash.
- Barrons.com•4 days ago
Pharma Stocks Are Starting to Look More Attractive
Healthcare has been a strong performer lately, and pharma stocks are garnering more interest from investors. Where we were: Worries about drug prices had been one knock against the pharma sector. Where we're headed: Investors are getting more interested in the stocks, on hopes that policy changes won't be a headwind.
- InvestorPlace•4 days ago
You Better Be Careful with Merck Stock, Especially at These Highs
Health care stocks including pharmaceutical giant Merck (NYSE:MRK) have gone on a nice run of late. Merk stock has gained over 20% just since early April, touching an all-time high this week. Q1 earnings that month seemed mixed, but the market reacted positively, and Merck raised guidance in the Q2 report late last month.
- American City Business Journals•4 days ago
In $270M Peninsula vaccine company buyout, small players look to be big shots
A deal with its roots in January's J.P. Morgan Healthcare Conference adds power to a small vaccine maker's quest to go after specialty vaccines amid a consolidating industry.
- Motley Fool•5 days ago
Carl Icahn Fires Shots at Express Scripts
Billionaire activist-investor Carl Icahn thinks Cigna’s planned tie-up with Express Scripts is a big blunder.
- Motley Fool•5 days ago
ICU Medical, Inc. (ICUI) Q2 2018 Earnings Conference Call Transcript
ICUI earnings call for the period ending June 30, 2018.
Market Realist•5 days agoSangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses
Sangamo Therapeutics reported second-quarter sales of $21.42 million, which just missed analysts’ estimate of $21.44 million in sales. This study evaluates SB-525 gene therapy for the treatment of hemophilia A. However, SGMO’s net loss declined on a sequential basis, and the company reported solid YoY (year-over-year) sales growth. Sangamo Therapeutics’ (SGMO) sales have risen ~160.0% on a YoY basis.
Market Realist•5 days agoCabozantinib Expected to Be Exelixis’s Long-Term Growth Driver
In the second quarter, Exelixis’s (EXEL) Cabometyx revenues grew ~74% YoY (year-over-year) to $141.1 million and ~9% sequentially. Cometriq generated revenues of $4.7 million, reflecting an ~11% sequential decline.
- Motley Fool•5 days ago
Why Sangamo Therapeutics, Inc. Stock Is Popping Today
The clinical-stage biotech reported encouraging news for its gene therapy targeting treatment of hemophilia A.
- Market Realist•5 days ago
Analysts’ Recommendations for Pfizer on August 6
Analysts expect Pfizer’s (PFE) adjusted EPS to be $2.99 on revenue of $54.3 billion in 2018, a 3.4% rise compared to $52.5 billion in 2017. Analysts also expect a 10.9% rise in the company’s adjusted net income during 2018, mainly due to a fall in its selling, general, and administrative expenses as well as its lower research and development expenses as a percentage of its sales.
- Zacks•5 days ago
Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well
Aerie's (AERI) Q2 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.
- Market Realist•5 days ago
Examining Pfizer’s Valuation as of August 6
Pfizer (PFE) is focused on discovering, developing, and manufacturing healthcare products. Pfizer’s portfolio includes medicines, vaccines, and consumer healthcare products. Pfizer’s top line rose ~4% to $13.5 billion in the second quarter of 2018 compared to $12.9 billion in the second quarter of 2017.
- Market Realist•6 days ago
A Look at Recent Developments at Pfizer
Pfizer’s (PFE) Innovative Health business is focused on developing and commercializing medicines, vaccines, and consumer healthcare products, while its Essential Health business includes legacy brands and generic products, research and development, and its contract manufacturing business.
- Motley Fool•6 days ago
Mylan N.V. (MYL) Q2 2018 Earnings Conference Call Transcript
MYL earnings call for the period ending June 30, 2018.
Market Realist•6 days agoEli Lilly Raised Its Non-GAAP Earnings Guidance for Fiscal 2018
In Eli Lilly’s (LLY) second-quarter earnings conference call, the company raised its fiscal 2018 non-GAAP EPS guidance from the previously projected range of $5.10–$5.20 to $5.40–$5.50. If we consider the midpoint of the guidance range, the guidance implies a rise of 27% YoY (year-over-year) in the company’s non-GAAP EPS in fiscal 2018. Eli Lilly reduced its fiscal 2018 GAAP EPS guidance from the previously projected range of $4.52–$4.62 to $3.19–$3.29 due to higher charges associated with in-process research and development related to the acquisition of ARMO BioSciences.
- Motley Fool•6 days ago
3 Top Dividend Stocks to Buy Right Now
If you're looking for stocks that generate income, look no further.
- InvestorPlace•6 days ago
Protagonist Stock Jumps 58% After Re-Review of Test Results
The mouth-watering 58% rise in shares of Protagonist Therapeutics (NASDAQ:PTGX) on Monday should interest biotech investors. At a market cap of $236.2 million, experienced biotech investors will expect higher than normal volatility. On Monday, Protagonist announced that it secured $22 million in equity financing through the sale of 2.75 million shares.
- CNBC Videos•6 days ago
After dismal earnings season, are we witnessing the reven...
Tech stocks surge back. Is it time to buy? With CNBC's Scott Wapner and the Fast Money traders, Pete Najarian, Tim Seymour, Karen Finerman and Guy Adami.
